Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001061 | 1.00 | UGT2B7 (0.44) | UGT2B7ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL19725736 | 0.85 | ALOX5 (0.41) | UGT2B7ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL1444769 | 0.85 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL6001013 | 0.79 | HPGD (0.42) | UGT2B7ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6001011 | 0.79 | HPGD (0.42) | UGT2B7ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6001008 | 0.79 | HPGD (0.42) | UGT2B7ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6001530 | 0.75 | GAA (0.52) | UGT2B7CYP1A2LMNAGAAHSD17B2 | |
| SCHEMBL6001527 | 0.75 | GAA (0.52) | UGT2B7CYP1A2LMNAGAAHSD17B2 | |
| SCHEMBL6001523 | 0.75 | GAA (0.52) | UGT2B7CYP1A2LMNAGAAHSD17B2 | |
| SCHEMBL7926582 | 0.74 | DYRK1A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | MUNSTER, UNIVERSITY OF (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1551392-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026253-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | XIAP, PIN1, NQO1 | UGT2B7 1358/4885ALOX5 652/4885CYP1A2 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.